01.12.2014 Views

Leuprolide inj - UMMC

Leuprolide inj - UMMC

Leuprolide inj - UMMC

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

<strong>Leuprolide</strong> <strong>inj</strong><br />

Trade name<br />

Drug class<br />

Presentation<br />

Prescriber<br />

Cost<br />

Indication<br />

Location<br />

Administration<br />

Stability / expiry<br />

Compatibility<br />

Incompatibility<br />

Special precautions<br />

Lucrin Depot 3.75mg/ Lucrin Depot 11.25mg<br />

Analog of naturally occurring Gonadotropin releasing hormone (GnRH or LH-RH)<br />

Kit contains 1vial of sterile lyophilized microsphere of leuprolide acetate<br />

incorporated in a biodegradable copolymer of lactic and glycolic acids, one ampoule<br />

of diluent; one syringe with 22 gauge needle and two alcohol wipes<br />

Consultant gynaecologist, urologist, oncologist and paediatric endocrinologist<br />

RM 310- Lucrin Depot 3.75mg<br />

RM 870- Lucrin Depot 11.25mg<br />

Endometriosis: 3.75mg monthly for a maximum of 6 months<br />

Uterine Fibroids: 3.75mg monthly for the treatment of anaemia caused by uterine<br />

leiomyomata in women who fail iron therapy.<br />

Prostate Cancer: 11.25mg 3 monthly for suppression of testosterone production<br />

Precocious Puberty: Dose is titrated upwards until down regulation is achieved<br />

Cawangan Pharm <strong>UMMC</strong>/ Kedai Pharm <strong>UMMC</strong><br />

Administered as a monthly IM or SC <strong>inj</strong>ection:<br />

• Using a syringe and 22 gauge needle, withdraw 1mL of diluent & <strong>inj</strong>ect into<br />

the vial.<br />

• Shake well to obtain a uniform suspension. Suspension will appear milky<br />

Room temperature. Shelf life :36 months<br />

Compatible fluids: NA<br />

Compatible drugs: NA<br />

Compatible via Y site: NA<br />

Compatible in syringe: NA<br />

Incompatible fluids: NA<br />

Incompatible drugs: NA<br />

Contraindication<br />

• Hypersensitivity to leuprolide acetate, similar nonapeptides or any of the<br />

excipents<br />

• Women who are or may become pregnant while receiving the drug<br />

Precautions<br />

• Bone mineral density changes can occur during any hypoestrogenic state, bone<br />

mineral density loss may be reversible after withdrawal of leuprolide acetate<br />

• Patient with metastatic vertebral lesions and or with urinary tract obstruction<br />

should be closely observed during the first few weeks of therapy.


• congestive heart failure or other conditions requiring sodium restriction<br />

• depression<br />

• history of thromboembolism or cardiovascular disease<br />

• increased risk of spinal cord compression<br />

• metastatic vertebral lesions<br />

• occurrence of memory disorders<br />

• transient worsening of prostate cancer symptoms (increased testosterone serum<br />

level)<br />

• undiagnosed abnormal vaginal bleeding<br />

Special notes • Lucrin 3.75mg is used monthly and 11.25mg is used three monthly<br />

• Goserelin or leuprolide has been approved for FOC supply to Government<br />

servants / dependants for treatment of CA prostate. (D&T Bil 5/2006 dated 13 Nov<br />

2006)<br />

• <strong>Leuprolide</strong> approved for 20 children / year to receive FOC supply for treatment<br />

of precocious puberty. Prescription must be written by Paediatric Endocrinologist.<br />

(D&T bil 1/2007 dated 12.1.2007)<br />

Patient Information Possible Side Effects: Increased bone pain, weakness, burning, or tingling of legs or<br />

feet, eecrease in how much or how often you urinate<br />

Prepared/checked by Tan Ching Hooi / PDS / HKD / PL<br />

Date compiled/edition 9 June 2008, 1 st edition

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!